Clinical Trial Update: Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating GSI-953 in healthy young volunteers and Alzheimer's disease patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• GSI-953 (GSI-953)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Alzheimer Disease | Phase 1 | Status: COMPLETED